Evidence map›Paper›PMID 35679272›Full record

ArticlePloS one2022

Identification of HCN1 as a 14-3-3 client.

Colten Lankford, Jon Houtman, Sheila A Baker

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Colten LankfordDepartment of Biochemistry and Molecular Biology, University of Iowa, Iowa City, Iowa, United States of America.
Jon HoutmanDepartment of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, United States of America.
Sheila A BakerDepartment of Biochemistry and Molecular Biology, University of Iowa, Iowa City, Iowa, United States of America.ORCID 0000-0002-0259-0652
University of Iowa · US

Funding

Protein Targeting in Vertebrate PhotoreceptorsR01EY020542 · NEI · UNIVERSITY OF IOWA · PI BAKER, SHEILA A · 2010 to 2021
$3.7M
NEI NIH HHS R01 EY020542
6 · The paper itself

Abstract

Hyperpolarization activated cyclic nucleotide-gated channel 1 (HCN1) is expressed throughout the nervous system and is critical for regulating neuronal excitability, with mutations being associated with multiple forms of epilepsy. Adaptive modulation of HCN1 has been observed, as has pathogenic dysregulation. While the mechanisms underlying this modulation remain incompletely understood, regulation of HCN1 has been shown to include phosphorylation. A candidate phosphorylation-dependent regulator of HCN1 channels is 14-3-3. We used bioinformatics to identify three potential 14-3-3 binding sites in HCN1. We confirmed that 14-3-3 could pull down HCN1 from multiple tissue sources and used HEK293 cells to detail the interaction. Two sites in the intrinsically disordered C-terminus of HCN1 were necessary and sufficient for a phosphorylation-dependent interaction with 14-3-3. The same region of HCN1 containing the 14-3-3 binding peptides is required for phosphorylation-independent protein degradation. We propose a model in which phosphorylation of mouse S810 and S867 (human S789 and S846) recruits 14-3-3 to inhibit a yet unidentified factor signaling for protein degradation, thus increasing the half-life of HCN1.

Indexed as

Hyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsPotassium ChannelsAnimalsCyclic Nucleotide-Gated Cation ChannelsHEK293 CellsHumansMiceNeuronsCyclic Nucleotide-Gated Cation ChannelsHcn1 protein, mouseHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsPotassium Channels

Identifiers

PMID35679272
PMCPMC9182292
OpenAlexW4285504912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.